Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Jun;14(6):792-5.
doi: 10.1128/CVI.00478-06. Epub 2007 Apr 11.

Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines

Suzanne M Garland  1 , Marc Steben, Mauricio Hernandez-Avila, Laura A Koutsky, Cosette M Wheeler, Gonzalo Perez, Diane M Harper, Sepp Leodolter, Grace W K Tang, Daron G Ferris, Mark T Esser, Scott C Vuocolo, Micki Nelson, Radha Railkar, Carlos Sattler, Eliav Barr; 012 Study Investigators
Affiliations
Randomized Controlled Trial

Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines

Suzanne M Garland et al. Clin Vaccine Immunol. 2007 Jun.

Abstract

The incorporation of multiple antigens into a single human papillomavirus (HPV) vaccine may induce immune interference. To evaluate whether interference occurs when HPV type 16 (HPV16) virus-like particles are combined in a multivalent vaccine, we conducted a study to evaluate anti-HPV16 responses among subjects receiving three-dose regimens of either a monovalent HPV16 vaccine or a quadrivalent HPV (types 6, 11, 16, and 18) vaccine.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Schematic of substudies 011 and 012 in the context of the larger efficacy study 013. HBV, hepatitis B virus.
FIG. 2.
FIG. 2.
Reverse cumulative distributions of anti-HPV16 levels in HPV vaccination groups at month 7 as determined by cLIA. The per-protocol immunogenicity population included all subjects who were not general protocol violators, received all three vaccinations within acceptable day ranges, were seronegative for HPV16 at day 1 and PCR negative from day 1 through month 7, and had a month 7 serum sample collected within an acceptable day range. The vertical line at 20 mMU/ml represents the seroconversion cutoff value for anti-HPV16. n, number of subjects contributing to the analysis.
See this image and copyright information in PMC

References

    1. Cates, W., Jr. 1999. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex. Transm. Dis. 26(4 Suppl.):S2-S7. - PubMed
    1. Dias, D., J. Van Doren, S. Schlottmann, S. Kelly, D. Puchalski, W. Ruiz, P. Boerckel, J. Kessler, J. M. Antonello, T. Green, M. Brown, J. Smith, N. Chirmule, E. Barr, K. U. Jansen, and M. T. Esser. 2005. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin. Diagn. Lab. Immunol. 12:959-969. - PMC - PubMed
    1. Edwards, K. M., and M. D. Decker. 1997. Combination vaccines consisting of acellular pertussis vaccines. Pediatr. Infect. Dis. J. 16(4 Suppl.):S97-S102. - PubMed
    1. Garland, S. M., M. Hernandez-Avila, C. M. Wheeler, G. Perez, D. M. Harper, S. Leodolter, G. W. K. Tang, D. G. Ferris, M. Steben, J. T. Bryan, F. J. Taddeo, R. Railkar, M. T. Esser, H. L. Sings, M. Nelson, J. Boslego, C. Sattler, E. Barr, and L. A. Kowtsky. Quadrivalent vaccine against human papillomavirus to prevent anogenital disease. N. Engl. J. Med., in press. - PubMed
    1. Miettinen, O., and M. Nurminen. 1985. Comparative analysis of two rates. Stat. Med. 4:213-226. - PubMed

Publication types

MeSH terms

LinkOut - more resources